Core Insights - BT Group has expanded its partnership with Optiva to implement innovative B2B and B2B2X network communication services, enhancing its capabilities in enterprise services [1][5] - The collaboration focuses on utilizing Optiva's cloud-native Application Server and Charging Engine to modernize BT Group's service offerings and create new revenue opportunities [1][2] Group 1: Partnership and Technology Implementation - The partnership aims to evolve BT Group from legacy technology to a modernized platform that supports increased 5G network coverage and flexible service creation [2][4] - Optiva's new interfaces and technologies are transforming BT Group's traditional network into a next-generation network, essential for both B2B and consumer applications [3][4] Group 2: Strategic Goals and Future Growth - The modernization of B2B applications is crucial for BT Group's service evolution, with a focus on enhancing network convergence capabilities [3][4] - Both companies are committed to a joint vision of expanding B2B and B2B2X services, which will drive BT Group's growth and technological advancements [5][4]

Core Insights - Opthea Limited has completed the final week 52 patient visit in the COAST Phase 3 trial, which evaluates the superiority and safety of sozinibercept combined with aflibercept for treating wet AMD [1][2] - Topline results from the COAST trial are expected in early Q2 CY25, while results from the ShORe trial are anticipated in mid-CY25 [1][2] Company Overview - Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) [3] - The lead product candidate, sozinibercept, is a first-in-class VEGF-C/D 'trap' inhibitor aimed at providing superior vision outcomes for wet AMD patients [4] Clinical Trials - Opthea is conducting two pivotal Phase 3 trials: COAST (combination of OPT-302 with Aflibercept) and ShORe (combination of OPT-302 with Ranibizumab) [2] - The primary endpoint for both trials is the mean change in Best Corrected Visual Acuity (BCVA) from baseline to week 52 [2] - Patients will continue treatment for an additional year post-week 52 to assess extended safety and tolerability [2] Regulatory Status - Sozinibercept has received Fast Track Designation from the US FDA for the treatment of wet AMD, which may facilitate its development and approval process [2]

Core Insights - Optiva Inc. has integrated agentic AI into its BSS platform, enhancing operational efficiency, reducing costs, and improving customer experience for telecom companies [1][3][5] - The technology leverages Google's Gemini models to enable intelligent process automation and hyper-personalized customer interactions [5][6] Industry Impact - By 2028, it is projected that 33% of enterprise software applications will incorporate agentic AI, a significant increase from 1% in 2024, indicating rapid adoption and potential for economic growth [4] - McKinsey identifies customer operations and sales as primary areas for GenAI revenue generation, highlighting the importance of AI agents in future business strategies [4] Benefits of Optiva's AI Solutions - Enhanced Customer Experience: The AI agent Amica automates customer queries, improving resolution times and satisfaction [9] - Increased Operational Efficiency: The AI agent Kairos reduces ticket resolution time and manual efforts, optimizing resource allocation [9] - Hyper-Personalized Engagement: The AI agent Sophos enables CSPs to offer tailored plans, enhancing sales efficiency and customer loyalty [9]

Core Viewpoint - Opthea Limited is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases, particularly wet age-related macular degeneration (wet AMD) [1][3]. Group 1: Company Overview - Opthea is listed on both ASX and NASDAQ under the ticker OPT [3]. - The company is developing therapies for vision-threatening eye diseases, including wet AMD and diabetic macular edema (DME), which are significant causes of vision loss globally [3]. Group 2: Product Development - Opthea's lead product candidate, sozinibercept, is currently in Phase 3 development and is a first-in-class VEGF-C/D 'trap' inhibitor [4]. - Sozinibercept is being evaluated in combination with standard anti-VEGF-A therapies, aiming to provide superior vision outcomes for wet AMD patients [4]. - This therapy has the potential to be the first new treatment in 20 years that allows wet AMD patients to lead fuller and healthier lives [4]. Group 3: Upcoming Events - Frederic Guerard, the CEO of Opthea, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 10:00 AM ET [2]. - The presentation will be available via webcast, which can be accessed through the company's website [2].

Core Viewpoint - Opthea Limited is set to present data on its lead product candidate, sozinibercept, at the Macula Society's 48th Annual Meeting, highlighting its potential advantages over standard treatments for wet age-related macular degeneration (wet AMD) [1][2]. Group 1: Company Overview - Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases, particularly wet AMD and diabetic macular edema (DME), which are significant causes of vision loss globally [3][4]. - The company's lead product candidate, sozinibercept, is a first-in-class VEGF-C/D 'trap' inhibitor currently in Phase 3 development [4]. Group 2: Presentation Details - The presentation titled "Sozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Subgroup Analysis of a Phase 2b Study to Assess the Angiographic Predictors of Response" will take place on February 14, 2025, from 8:00 to 8:05 AM ET [2]. - Dr. David S. Boyer will present findings indicating that sozinibercept 2 mg combination therapy resulted in superior vision and anatomical outcomes compared to the standard-of-care treatment, ranibizumab [2].

Core Insights - Opthea Limited is preparing for an Investor Day on January 28, 2025, in New York City, followed by presentations in Sydney and Melbourne, to discuss the anticipated topline data from its pivotal trials for sozinibercept in wet AMD [1][2][3] Company Overview - Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) [8][9] - The lead product candidate, sozinibercept, is currently being evaluated in two pivotal Phase 3 clinical trials (COAST and ShORe) aimed at improving efficacy and vision outcomes when used in combination with standard anti-VEGF-A therapies [9] Management and Expertise - The Investor Day will feature presentations from Charles C. Wykoff, MD, PhD, a leading retina specialist and Chief Investigator for the COAST trial, and Mike Campbell, Chief Commercial Officer, who has extensive experience in launching treatments for retinal diseases [4][5][6] Event Details - The New York event will include a live webcast and a question-and-answer session, concluding around 3:00 PM ET, with a replay available on the company's website [2] - In-person presentations will also take place in Sydney on February 3 and Melbourne on February 5, 2025 [3]

Phase 1b clinical data underpins sozinibercept's potential as a novel, first-in-class VEGF-C/D ‘trap' to improve visual and anatomic outcomes in DME Published in peer-reviewed journal Translational Vision Science & Technology and included in the Anti-VEGF Special Journal Issue of ARVO DME program to be advanced after wet AMD topline data readout anticipated for COAST in early CY Q2 2025 and ShORe in mid-2025 MELBOURNE, Australia and PRINCETON, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:O ...

Business update to include masked Phase 3 patient demographics and baseline characteristics Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California MELBOURNE, Australia and PRINCETON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced ...

MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy. FLORetina aims to p ...

Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointme ...